Abstract 370P
Background
Immune checkpoint inhibitors (ICI) have proven efficacy in R/M HNSCC. In LMICs, <5% of patients have access to ICI at approved doses. We assessed the efficacy of low dose ICI in locally advanced/inoperable HNSCC.
Methods
We conducted retrospective analysis of patients with locally advanced/inoperable HNSCC who underwent induction chemotherapy with low dose nivolumab. Eligible doses of nivolumab were <3mg/kg q2w with chemotherapy backbone of TPX or TP+/- OMCT. The principal outcomes were conversion to radical therapy, ORR, PFS and OS.
Results
We included 111 patients, 78.4% males with median age 48. Primary sites- oral cavity(71.2%), hypopharynx(11.7%), oropharynx(9%) and larynx(8.1%) mainly stage IVA/IVB. TPX/TP was used in 95.4%. Nivolumab 20/40/100 mg all 2/3/4 weeks were the doses and intervals. The harmonized median dose of nivolumab was 0.51 mg/kg q2w (median 3 doses). Response assessment was available for 92 of 111 patients- CR in 7 (6.3%), PR in 65(58.6%), SD in 12(10.8%), PD in 8(7.2%). ORR was 78.2% in those assessed. 25(31.6%) oral cavity tumours became resectable following induction, of whom, 8(32%) had pCR. 60% of oropharyngeal, 69% of hypopharynx and 77.8% of larynx primary site underwent radical RT/CRT after induction. Median PFS is 18.6 months. PFS and OS at 1 year were 64.6% and 82.6%. Median PFS not reached in the cohort with pCR/rCR and 18 months in the group without(p 0.03). No recurrence/death observed thus far in those with pCR. At nivolumab doses <0.6mg/kg, median PFS was significantly lower (13 months vs NR; p 0.04). The retrospective design introduces potential confounders. Grade 3/4 AEs were neutropenia (14.4%), CINV (2.7%), anemia(2.7%), mucositis(1.8%) and febrile neutropenia(1%); Any grade hyponatremia(14%), hypothyroidism(5%).
Conclusions
Low-dose ICI with induction chemotherapy demonstrated promising ORR and conversion to radical therapy. Survival, although immature, appears favourable, especially for patients with pCR/rCR. Doses of nivolumab < 0.6mg/kg may compromise survival. Low-dose (1/6th of standard dose) regimens could enhance ICI access in LMICs due to significantly reduced costs and merit investigation in randomised trials to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board (Ethics committee) of the Christian Medical College Vellor.
Funding
Has not received any fundin.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract